Drug intelligence / Profile preview

TGW-111

Development stage: Preclinical
Lead developer: Tagworks Pharmaceuticals
Modality: Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

TGW-111 is an antibody-drug conjugate (ADC) developed by Tagworks Pharmaceuticals. It is currently in the discovery phase of research and development. The drug is being investigated for use in oncology, specifically for the treatment of solid tumors (neoplasms). As an ADC, TGW-111 likely consists of a monoclonal antibody linked to a cytotoxic agent, designed to selectively deliver the cytotoxic payload to cancer cells expressing a specific target antigen. However, detailed information about its precise mechanism of action or molecular target has not been disclosed publicly[1].

Beyond the preview

Go deeper on TGW-111.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TGW-111.

Explore the full profile